156 related articles for article (PubMed ID: 19581457)
1. In vitro activities of telavancin and six comparator agents against anaerobic bacterial isolates.
Finegold SM; Bolanos M; Sumannen PH; Molitoris DR
Antimicrob Agents Chemother; 2009 Sep; 53(9):3996-4001. PubMed ID: 19581457
[TBL] [Abstract][Full Text] [Related]
2. In vitro activities of the new semisynthetic glycopeptide telavancin (TD-6424), vancomycin, daptomycin, linezolid, and four comparator agents against anaerobic gram-positive species and Corynebacterium spp.
Goldstein EJ; Citron DM; Merriam CV; Warren YA; Tyrrell KL; Fernandez HT
Antimicrob Agents Chemother; 2004 Jun; 48(6):2149-52. PubMed ID: 15155214
[TBL] [Abstract][Full Text] [Related]
3. Comparative in vitro activities of SMT19969, a new antimicrobial agent, against Clostridium difficile and 350 gram-positive and gram-negative aerobic and anaerobic intestinal flora isolates.
Goldstein EJ; Citron DM; Tyrrell KL; Merriam CV
Antimicrob Agents Chemother; 2013 Oct; 57(10):4872-6. PubMed ID: 23877700
[TBL] [Abstract][Full Text] [Related]
4. In vitro activity of telavancin against resistant gram-positive bacteria.
Krause KM; Renelli M; Difuntorum S; Wu TX; Debabov DV; Benton BM
Antimicrob Agents Chemother; 2008 Jul; 52(7):2647-52. PubMed ID: 18443122
[TBL] [Abstract][Full Text] [Related]
5. Antimicrobial Activity of Telavancin Tested
Duncan LR; Sader HS; Huband MD; Flamm RK; Mendes RE
Microb Drug Resist; 2020 Aug; 26(8):934-943. PubMed ID: 32049591
[TBL] [Abstract][Full Text] [Related]
6. Antimicrobial activity of eravacycline and other comparative agents on aerobic and anaerobic bacterial pathogens in Taiwan: A clinical microbiological study.
Tsai MH; Chen CL; Chang HJ; Chuang TC; Chiu CH
J Glob Antimicrob Resist; 2024 Jun; 37():93-99. PubMed ID: 38552878
[TBL] [Abstract][Full Text] [Related]
7. Telavancin activity in vitro tested against a worldwide collection of Gram-positive clinical isolates (2014).
Duncan LR; Sader HS; Smart JI; Flamm RK; Mendes RE
J Glob Antimicrob Resist; 2017 Sep; 10():271-276. PubMed ID: 28735051
[TBL] [Abstract][Full Text] [Related]
8. Comparative surveillance study of telavancin activity against recently collected gram-positive clinical isolates from across the United States.
Draghi DC; Benton BM; Krause KM; Thornsberry C; Pillar C; Sahm DF
Antimicrob Agents Chemother; 2008 Jul; 52(7):2383-8. PubMed ID: 18443115
[TBL] [Abstract][Full Text] [Related]
9. Comparative in vitro activities of LFF571 against Clostridium difficile and 630 other intestinal strains of aerobic and anaerobic bacteria.
Citron DM; Tyrrell KL; Merriam CV; Goldstein EJ
Antimicrob Agents Chemother; 2012 May; 56(5):2493-503. PubMed ID: 22290948
[TBL] [Abstract][Full Text] [Related]
10. The in-vitro activity of trovafloxacin and nine other antimicrobials against 413 anaerobic bacteria.
Bowker KE; Wootton M; Holt HA; Reeves DS; MacGowan AP
J Antimicrob Chemother; 1996 Aug; 38(2):271-81. PubMed ID: 8877542
[TBL] [Abstract][Full Text] [Related]
11. [In vitro activity of sitafloxacin against clinical isolates in 2009].
Amano A; Matsuzaki K; Kishi N; Saika T; Hasegawa M; Ikeda F; Matsumoto T; Yamaguchi H; Kanda Y; Shiozawa T
Jpn J Antibiot; 2010 Dec; 63(6):411-30. PubMed ID: 21425595
[TBL] [Abstract][Full Text] [Related]
12. Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
Haas W; Pillar CM; Zurenko GE; Lee JC; Brunner LS; Morris TW
Antimicrob Agents Chemother; 2009 Aug; 53(8):3552-60. PubMed ID: 19506065
[TBL] [Abstract][Full Text] [Related]
13. Activity of OPT-80, a novel macrocycle, compared with those of eight other agents against selected anaerobic species.
Credito KL; Appelbaum PC
Antimicrob Agents Chemother; 2004 Nov; 48(11):4430-4. PubMed ID: 15504874
[TBL] [Abstract][Full Text] [Related]
14. Postantibiotic effects of telavancin against 16 gram-positive organisms.
Pankuch GA; Appelbaum PC
Antimicrob Agents Chemother; 2009 Mar; 53(3):1275-7. PubMed ID: 19124659
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of the in vitro activity of levornidazole, its metabolites and comparators against clinical anaerobic bacteria.
Hu J; Zhang J; Wu S; Zhu D; Huang H; Chen Y; Yang Y; Zhang Y
Int J Antimicrob Agents; 2014 Dec; 44(6):514-9. PubMed ID: 25301712
[TBL] [Abstract][Full Text] [Related]
16. Worldwide appraisal and update (2010) of telavancin activity tested against a collection of Gram-positive clinical pathogens from five continents.
Mendes RE; Sader HS; Farrell DJ; Jones RN
Antimicrob Agents Chemother; 2012 Jul; 56(7):3999-4004. PubMed ID: 22508304
[TBL] [Abstract][Full Text] [Related]
17. Worldwide summary of telavancin spectrum and potency against Gram-positive pathogens: 2007 to 2008 surveillance results.
Putnam SD; Sader HS; Moet GJ; Mendes RE; Jones RN
Diagn Microbiol Infect Dis; 2010 Aug; 67(4):359-68. PubMed ID: 20638605
[TBL] [Abstract][Full Text] [Related]
18. Update of the telavancin activity in vitro tested against a worldwide collection of Gram-positive clinical isolates (2013), when applying the revised susceptibility testing method.
Mendes RE; Farrell DJ; Sader HS; Streit JM; Jones RN
Diagn Microbiol Infect Dis; 2015 Apr; 81(4):275-9. PubMed ID: 25618421
[TBL] [Abstract][Full Text] [Related]
19. The growth-inhibitory properties of meropenem against anaerobes of clinical importance.
Watt B; Naden M
J Antimicrob Chemother; 1989 Sep; 24 Suppl A():119-24. PubMed ID: 2808203
[TBL] [Abstract][Full Text] [Related]
20. Telavancin Activity against gram-positive bacteria isolated from patients with skin and skin-structure infections.
Pfaller MA; Rhomberg PR; Sader HS; Mendes RE; Jones RN
J Chemother; 2010 Oct; 22(5):304-11. PubMed ID: 21123152
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]